



Endocrine and Neuroendocrine Cancers

Guest Editors:

Prof. Dr. Alfredo Berruti

Dr. Vito Amoroso

Dr. Nicola Fazio

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editors

Dear Colleagues,

Endocrine and neuroendocrine tumors represent heterogeneous diseases that have an endocrine cell onset as a common denominator. Many of these neoplasms are relatively rare and may be included in genetic syndromes. Their treatment is often challenging and requires a multidisciplinary approach. In recent years, we have witnessed an improvement in the biological and pathogenetic knowledge of these diseases, and new effective drugs have been identified.

This Special Issue will focus on the current state of the art and future prospects in a) diagnosis, b) genetics, c) biology and genomics, d) multidisciplinary approaches and the effectiveness of currently available therapies, and e) new molecular targeted therapies and immunotherapies.

Prof. Alfredo Berruti

Dr. Vito Amoroso

Dr. Nicola Fazio

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)